Form 4: AVADEL Director Transfers 11,000 Stock Options to Trust

AVADEL Pharmaceuticals PLC Director Linda Palczuk transferred 11,000 stock options with an exercise price of $10.83 to a revocable trust on September 15, 2025.

Summary

• Linda Palczuk, a Director of AVADEL Pharmaceuticals PLC, reported changes in her beneficial ownership of company securities.
• She was granted 11,000 stock options to purchase Ordinary Shares.
• The exercise price for these stock options is $10.83 per share.
• The options are scheduled to vest in full on the earlier of July 29, 2026, or the date of the next annual general meeting of shareholders following the grant date, subject to her continued service.
• On September 15, 2025, she transferred these 11,000 options to a revocable trust, of which she is the trustee, changing the form of ownership from direct to indirect.
• The expiration date for these stock options is July 29, 2035.

Sentiment

Score: 5

Explanation: This is a routine disclosure of an insider transaction (grant and transfer of stock options) and does not inherently indicate positive or negative sentiment for the company's operational or financial performance.

Positives

• The grant of 11,000 stock options to Director Linda Palczuk aligns her financial interests with the long-term performance and shareholder value creation of AVADEL Pharmaceuticals PLC.

Future Outlook

The 11,000 stock options granted to Director Linda Palczuk are scheduled to vest on the earlier of July 29, 2026, or the date of the next annual general meeting of shareholders following the grant date, contingent on her continued service.

Industry Context

This transaction represents a routine equity compensation event for a director, common across publicly traded companies to align management and director incentives with shareholder interests within the pharmaceutical industry.

Comparison to Industry Standards

• The grant of stock options is a common form of equity compensation for directors in the pharmaceutical industry, aiming to align their incentives with company performance.
• The specific terms, such as the 11,000 options and $10.83 exercise price, are determined by AVADEL's compensation committee, likely based on peer benchmarking, though no specific comparative data or benchmarks are provided in this filing.

Corporate Governance

Related Party Transactions

• Transfer of 11,000 stock options to a revocable trust where the reporting person, Linda Palczuk, serves as trustee.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decisions.
• Director (Linda Palczuk): Receives equity compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• Vesting of the 11,000 stock options on the earlier of July 29, 2026, or the next annual general meeting, subject to continued service.

Key Dates

Keywords

AVDL, Avadel Pharmaceuticals, Linda Palczuk, Director, Stock Options, Beneficial Ownership, SEC Form 4, Trust Transfer, Equity Compensation